Intermediate assessment of the results of a clinical study of a neoadjuvant combined treatment of patients with high-risk and very high-risk prostate cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Man's capacities have never been measured; nor are we to judge of what he can do by any precedents, so little has been tried. Henry David Thoreau Background. Prostate cancer is the leading medical and social problem of the male population. Thousands of men die from this pathology every year. The article reviews the results of various strategies for the treatment of high-risk and very high-risk prostate cancer, as well as the materials of authors’ own research. Objective. Improvement of the effectiveness of treatment of patients with high-risk and very high-risk prostate cancer. Methods. Data on patients with patients with high-risk and very high-risk prostate cancer, who received treatment in the N.N. Petrov NMRCO from 2014 to 2018. Results. In this article, we present the intermediate assessment of data of a group of patients (n=46) who received only combined treatment (neoadjuvant therapy with docetaxel+degarelix followed by radical prostatectomy). 28 patients (61%) received full treatment. In five patients, completion of the neoadjuvant therapy stage was not possible due to the progression of the disease (increase in PSA level after a previous pronounced decrease, n=2), the presence of comorbidities/adverse events (n=2), death by home accident (n=1). As a result of the use of neoadjuvant drug treatment, a statistically significant (p=0.004) decrease in the volume of the prostate gland and PSA level (p=0.008) was achieved. Assessment of the safety of neoadjuvant drug treatment of high-risk and very high-risk prostate cancer patients revealed an acceptable toxicity profile. The frequency of grade 3-4 hematological complications was 21% (n=6). Non-hematological adverse events developed in 43% (n=12) of patients, with grade 3-4 - in 7% (n=2). Given the prospective nature of the research, it is planned to continue trial until the solution of the tasks set (the evaluation of therapeutic pathomorphosis, molecular genetic markers). Conclusion. Neoadjuvant therapy with docetaxel and degarelix is associated with improved results of treatment of patients with highrisk and very high-risk prostate cancer. The treatment regimen used showed an acceptable tolerability and toxicity profile.

全文:

受限制的访问

作者简介

Natalia Buevich

N.N. Petrov National Medical Research Center of Oncology

Email: buevich_nn@mail.ru
Oncologist, Postgraduate Student at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Nosov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. Reva

N.N. Petrov National Medical Research Center of Oncology; Pavlov First St. Petersburg State Medical University

Clinic of Urology St. Petersburg, Russia

A. Artemyeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. Berkut

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

参考

  1. Чиссов В.И., Мерабишвили В.М., Старинский В.В. и др. Злокачественные новообразования в мире, России, Санкт-Петербурге. СПб. 2007;69-102.
  2. Heidenreich A., Bastian P.J., Bellmunt J., et. al. EAU guidelines on prostate cancer. Part ll: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002.
  3. DAmico A.V, Whittington R., Malkowicz B.S., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74.
  4. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. doi: 10.3322/caac.21208.
  5. Mcleod D.G. Hormonal therapy: historical perspective to future directions. Urology. 2003 61(1):3-7.
  6. Nosov A., Reva S., Petrov S., et al. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study. Prostate. 2016;76(15):1345-52. doi: 10.1002/pros.23165.
  7. Mottet N., Bellmunt J., Briers E. Guidelines on prostate cancer. European Association of Urology. 2015.
  8. Носов Д.А., Гладков О.А., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2017;7:421-32.
  9. Nanda A., Chen M.H., Renshaw A.A., et al. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. lnt J Radiat Oncol Biol Phys. 2009;74(5):1419-23. doi: 10.1016/j.ijrobp.2008.10.027.
  10. Nader R., Joelle El Amm, Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-29. doi: 10.4103/aja.aja_40_17.
  11. Cronin A., Goboy G., Vickers A. Definition of biochemical recurrence after radical prostatectomy does not substantially impact estimates for prognostic factors. J Urol. 2010;183(3):984-89.
  12. Велиев Е.И., Соколов Е.А., Лоран О.Б. и др. Рак предстательной железы высокого риска: онкологическая эффективность радикальной простатэктомии. Онкоурология. 2014;53-7
  13. Sundi D., Wang V.M., Pierorazio PM., et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis. 2014;17(1):57-63. doi: 10.1038/pcan.2013.46.
  14. Soares R., Eden G. Surgical treatment of highrisk prostate cancer. Minerva Urol Nefrol 2015;67(1):33-46.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2019
##common.cookie##